Benitec Biopharma
BNTC
57 hedge funds and large institutions have $265M invested in Benitec Biopharma in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 5 closing their positions.
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
54% more funds holding
Funds holding: 37 → 57 (+20)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0.53% more ownership
Funds ownership: 85.89% → 86.42% (+0.53%)
9% less capital invested
Capital invested by funds: $290M → $265M (-$24.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.98M |
| 2 |
BlackRock
New York
|
+$7.47M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.54M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.96M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Infinitum Asset Management
Fort Lauderdale,
Florida
|
-$8.74M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.92M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.23M |
| 4 |
Millennium Management
New York
|
-$417K |
| 5 |
LP
Longaeva Partners
Chicago,
Illinois
|
-$392K |
BNTC Hedge Fund Activity: Q2 2025 in Review
57 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2025, worth a combined $265M — down 8.6% from $290M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BNTC positions and 5 closed out — a net gain of 20 holders — while 13 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $8.98M. The largest seller was Infinitum Asset Management, cutting an estimated $8.74M.
- 57 institutional investors held Benitec Biopharma (BNTC) as of Q2 2025, up from 37 in Q1 2025.
- Funds reported $265M of Benitec Biopharma stock for Q2 2025, down 8.6% quarter-over-quarter.
- 25 funds opened new Benitec Biopharma positions in Q2 2025 and 5 closed out, a net change of +20 holders.
- The largest Benitec Biopharma buyer in Q2 2025 was Vanguard Group, an estimated $8.98M added.
- The largest Benitec Biopharma seller in Q2 2025 was Infinitum Asset Management, an estimated $8.74M sold.
Based on aggregated 13F filings for Q2 2025.